NCT04773782: A Study of Avapritinib in Pediatric Patients With Relapsed or Refractory Solid Tumors With a Mutation in KIT or PDGFRA

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: PDGFR, KIT
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 2 Years to 17 Years (Child
Location of Metastases: Brain
Additional Notes: Patients without brain metastasis are still eligible
Exclusions: Patients who have previously received treatment with avapritinib; Patients 18 years of age or older

Comments are closed.

Up ↑